Ripple Science offers a machine-learning enabled patient engagement platform—Ripple Essentials, Ripple Pro and Ripple Enterprise—that advances patient recruitment and management in clinical research. The suite delivers automation, analytics and insights for research sites, coordinating/call centers, CROs and sponsors, and is HIPAA‑compliant and SOC‑2 certified. Ripple applies data‑driven analytics, machine learning and AI‑enabled algorithms to speed enrollment, reduce dropouts and improve retention and diversity across traditional, remote, decentralized and hybrid trials. The company was spun out of the University of Michigan in 2016 and is based in Ann Arbor, Michigan. Ripple recently secured an additional $1.5 million in growth capital and says it will use findings from a newly formed Industry and Scientific Advisory Board to guide deployment of its platform. The advisory board, chaired by Jeanne Hecht and including Drs. Amir Kalali and Jeff Kingsley, will meet quarterly to identify customer needs, product opportunities and market challenges. Ripple Science offers a HIPAA-compliant SaaS platform that manages participant recruitment and retention across all trial stages and provides real-time analytics to track progress and mitigate risks. The platform centralizes communication and enables researchers to automatically build participant registries that can be shared and leveraged for future trials. Ripple's flagship product is used by research investigators at more than 100 academic and research centers worldwide, including Johns Hopkins University, Pennsylvania State University, UCLA, Brain Research Foundation Canada, University of East Anglia, Cognito Therapeutics and the University of Michigan. Led by President and CEO Peter Falzon, the company plans to use the new funding to scale sales and marketing and expand its commercial reach among private and public clinical research organizations. Ripple completed a $2.5M equity financing round. The company is based in Ann Arbor, Michigan.

Total raised

$4M

Funding rounds

2

Latest round

Equity

Latest activity

Aug 2021